Characterization of the calcium and chloride [3H]glutamate binding site in crude synaptic membranes from human brain tissue.

1. The specific binding properties of [3H]glutamate to crude synaptic membranes (CSM) from postmortem human brain were studied. 2. Equilibrium binding analysis of [3H]glutamate binding to CSM from human brain cortex revealed a KD = 110 +/- 12 nM and a Bmax = 27 +/- 4 pmol/mg protein). 3. Calcium increased the number of binding sites, Bmax = 44 +/- 6 pmol/mg protein, without a significant change in the affinity constant, KD = 95 +/- 10 nM. 4. The dissociation constant of the [3H]glutamate bound to human CSM was 4.0 +/- 0.4 min-1 (n = 3). 5. The relative potencies of glutamate analogs and 2-amino-4-phosphonobutyric acid (APB) to compete for the glutamate binding sites, in human CSM, were glutamate > quisqualate = ibotenic acid > APB >> alpha-amino-3-hydroxy-5-methyl-4-isoxozolepropionate acid. 6. The glutamate specific binding in CSM from postmortem human brain was particularly rich in the gyrus hippocampus, nucleus accumbens, thalamus and frontal cortex. 7. This glutamate binding protein is related, probably, to a presynaptic neurosecretory pathway.

Characterization of the nipecotic binding to rat brain membranes.

1. The specific binding of [3H]Nip and [3H]GABA to rat brain membranes has been reexamined. 2. Specific binding of [3H]Nip and [3H]GABA was exclusively dependent on sodium ions in a cooperative manner (Hill coefficient 2.2 +/- 0.2 and 2.4 +/- 0.3 for [3H]Nip and [3H]GABA binding, respectively). Potassium, lithium or choline chloride salts were ineffective for replacing NaCl. 3. Maximal binding was observed at 2 degrees C. The association constants were K+1 = 0.033 min-1 microM-1 for [3H]GABA. The dissociation constants obtained by the addition of 1 mM of non-labeled GABA were 0.087 +/- 0.01 min-1 and 0.139 +/- 0.025 min-1 for [3H]Nip and [3H]GABA, respectively. Scatchard curves were in agreement with these constants, KD = 1.6 microM for [3H]GABA and 2.6 microM for [3H]Nip with equal Bmax = 138 pmol per mg protein. 4. The dissociation constants for [3H]Nip bound increased from 0 to 0.035, 0.18 and 0.58 min-1 at 2, 16, 26 and 37 degrees C, respectively, contrary to the hydrophobic derivate of nipecotic acid, NO 328. 5. Pharmacological characterization and regional brain distribution of [3H]Nip and [3H]GABA binding and uptake, suggest that [3H]Nip specifically labels the neuronal GABA uptake system, absent in peripheral tissues.

The activity of zolpidem and other hypnotics within the gamma-aminobutyric acid (GABAA) receptor supramolecular complex, as determined by 35S-t-butylbicyclophosphorothionate (35S-TBPS) binding to rat cerebral cortex membranes.

The present study compares the effects of different hypnotics acting at omega 1/omega 2 sites (zolpidem, zopiclone, flunitrazepam and triazolam) on 35S-t-butylbicyclophosphorothionate (35S-TBPS) binding to well-washed rat cerebral membranes, in the presence of 1M NaCl. Under these conditions, all compounds enhanced 35S-TBPS binding in the 0.05 to 10 microM range with EC50 values and maximal enhancement of: zolpidem, 84 nM and 36%; flunitrazepam, 8 nM and 41%; zopiclone, 171 nM and 51%; triazolam, 2 nM and 42%. Under these conditions, gamma-aminobutyric acid enhanced 35S-TBPS binding with an EC50 of 240 nM and a 38% maximal increase. The EC50 values for the stimulation of 35S-TBPS binding are well correlated, with (r = 0.97) the affinity of these compounds at omega 1/omega 2 sites, and are in the same concentration range. This enhanced binding was due to an altered apparent affinity for the 35S-TBPS recognition site without any change in the number of sites (Scatchard analysis). The effect of zolpidem and other hypnotics was antagonized by flumazenil. This was an apparently competitive antagonism in the case of zolpidem or flunitrazepam, whereas for zopiclone, increasing the concentration of the hypnotic did not overcome the antagonism. Bicuculline only partially antagonized the hypnotic-induced enhancement of 35S-TBPS binding. This antagonism was more effective for zopiclone (-57%) than for either zolpidem (-33%) or flunitrazepam (-30%). Zolpidem and the other hypnotics studied induced a fast component of dissociation which was not observed in the control membranes. These findings are consistent with the hypothesis that omega 1/omega 2 agonists increase the frequency of openings of the chloride ionophore, with both gamma-aminobutyric acid-A receptor-dependent and -independent mechanisms.

Evidence that clomethiazole interacts with the macromolecular GABA A-receptor complex in the central nervous system and in the anterior pituitary gland.

Clomethiazole (CLOM) is known to be an anticonvulsant drug and has been also reported to decrease serum prolactin (PRL) in humans. Both effects may be mediated by an enhancement of gabaergic transmission. In order to determine if (CLOM) interacts with GABA metabolism and/or at the GABA receptor level, we studied its effect on PRL release and on the binding of various compounds that interact with the GABAA-benzodiazepine-receptor complex. Intraperitoneal (IP) administration of CLOM to rats significantly decreased PRL levels, and this effect was antagonized by IP administration of bicuculline, an antagonist of the GABAA receptor. In vitro, the inhibitory effect of muscimol on PRL release from rat hemiadenohypophysis was potentiated in a dose-dependent manner by preincubation with CLOM. This effect was antagonized by picrotoxin (10(-6) M). On the other hand, CLOM had no effect on GABA metabolism and did not compete with GABAA, GABAB or benzodiazepine binding sites in cortical membranes. CLOM competed, however, with the picrotoxin binding site labelled with [35S]-butylbicyclophosphorothionate (TBPS), at an IC50 value of 1.2 x 10(-4) M, which is in the same range as some barbiturates. These results concerning PRL release and binding experiments with cortical membranes suggest that CLOM interacts with the picrotoxin/barbiturate site of the GABAA-receptor-chloride channel complex.

Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties.

The effects of the anti-ischemic agents ifenprodil and its derivative SL 82.0715 ((+/-)-alpha-(4-chlorophenyl)-4-[(4-fluorophenyl) methyl]-1-piperidineethanol] have been analyzed in a number of models indicative of N-methyl-D-aspartate (NMDA) antagonistic potential in vitro and in vivo. Ifenprodil and SL 82.0715 potently and noncompetitively antagonize the stimulatory effects of NMDA on cyclic GMP production in immature rat cerebellar slices (IC50 values, 0.4 and 10 microM, respectively), as well as the NMDA-evoked [3H]acetylcholine release in adult rat striatal slices (IC50 values, 1.6 and 6.6 microM, respectively). Ifenprodil is 10 times more potent than (+/-)3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) but less active than the reference noncompetitive NMDA channel blockers [MK 801, ((+)-5-methyl-10,11-dihydro-5H-dibenzo-[a,d]cyclohepten-5,10-imine ], phencyclidine and 1-[1-(2-thienyl)cyclohexyl]piperidine (TCP)] in these models. Ifenprodil and SL 82.0715 partially displace (maximal displacement 40-50% at 10 microM) the NMDA receptor ligand [3H]CPP from its binding site to rat brain membranes (IC50 values, 0.1 and 0.3 microM, respectively) in a noncompetitive manner; in the micromolar range the two agents also partially displace the NMDA channel ligand [3H]TCP from its binding site to rat brain membranes, and noncompetitively antagonize the L-glutamate-induced increase in [3H]TCP binding. Ifenprodil (0.01-1 microM) partially antagonizes the depolarizing effects of NMDA on the immature rat hemisected spinal cord in vitro. In mouse cultured spinal cord neurons, ifenprodil dose-dependently antagonizes the depolarizing effects of micropressure applied NMDA. Inhibition of the effects of NMDA in this model by ifenprodil and SL 82.0715 is noncompetitive. In vivo and after systemic i.p. administration, ifenprodil and SL 82.0715 antagonize the stimulatory effects of intrastriatally dialyzed NMDA on striatal dopamine release in rats (ID50 values, 0.9 and 0.3 mg/kg, respectively), and block the harmaline-evoked increase in cerebellar cyclic GMP production in mice (ID50 values, 3 and 4 mg/kg, respectively). These results indicate that ifenprodil is a noncompetitive NMDA antagonist which has a mechanism of action distinct from either the reference competitive NMDA receptor antagonists (CPP and 2-amino-5-phosphonovalerate) or the noncompetitive NMDA channel blockers (phencyclidine, TCP and MK 801). The potent NMDA antagonistic effects of the ifenprodil class of compounds are likely to be related to the demonstrated anti-ischemic potential of these compounds.

Differentiation of activities within the GABAA-chloride ionophore complex by means of 35-S-TBPS binding.

From the above results, it is evident that both alpidem and zolpidem modulate the GABAA receptor linked chloride ionophore in an allosteric manner via omega 1 anxiolytic/hypnotic recognition sites. As both are highly specific for the omega 1 site, with little affinity for the omega 2 site, it appears that omega 1 site activation is sufficient to fully engage the various linkages within the GABAA receptor supramolecular complex, resulting in modulation of the chloride ionophore. This action is related to an enhanced affinity of the recognition site for TBPS. Under the present conditions (high sodium chloride, frozen well-washed membranes), several (but not all, e.g. zolpidem) anxiolytics and hypnotics decreased TBPS binding at very high (100-500 microM) concentrations. This effect is unlikely related to the pharmacological activity of these compounds, as it is insensitive to flumazenil and occurs only at concentrations which would be supra-toxic. In contrast, the enhancement of TBPS binding by these anxiolytics and hypnotics occurs within the range of, and correlates with, their therapeutic plasma levels and their affinity for omega 1/omega 2 receptors. The present findings suggest that a different degree of linkage for different compounds occurs between the GABAA receptor and the omega 1/omega 2 receptor mediated enhancement of TBPS binding, as the action of alpidem is completely reversed by bicuculline, whereas for zopidem and flunitrazepam a component of the TBPS enhancement is bicuculline insensitive. A Ro 5-4864 sensitive site (probably not the omega 3 site) occurs with the GABAA receptor supramolecular complex, which apparently participates in the enhancement of TBPS binding.(ABSTRACT TRUNCATED AT 250 WORDS)

Upregulation of gamma-aminobutyric acid (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock.

The action of different classes of clinically effective antidepressants and electroshock on gamma-aminobutyric acid (GABA) B recognition sites in the frontal cortex was compared to that of other psychotropic agents. After either prolonged (6-18 days) s.c. infusion via osmotic minipumps or repeated i.p. injections of different antidepressants, or a series of electroshocks, treatment was halted and 72 hr later the animals were sacrificed, the brain was dissected and frozen. All major antidepressants (desipramine, amitryptyline or maprotiline), several newer compounds with reported antidepressant activity (viloxazine, zimelidine, fluoxetine, citalopram, progabide, fengabine, sodium valproate, mianserin, trazodone or nomifensine) as well as pargyline and repeated electroshocks, up-regulated GABA B binding in the rat frontal cortex but not hippocampus. This appeared to be a maximum binding effect, but in some instance the kinetics were more complex. Reserpine, diphenylhydantoin and phenobarbital down-regulated GABA B binding in the frontal cortex, whereas this was unaltered by haloperidol, chlorpromazine or diazepam administration. Desipramine up-regulated GABA B binding in a dose- and time-dependent manner (minimum effective dose, 1.25 mg/kg/day s.c. for 18 days; onset of action, 6 days at 5 mg/kg/day s.c.). Together with the rather sparse data in the literature on GABA in depression and antidepressant drug action, these findings support a common GABAergic mechanism of action of antidepressant drugs and electroshock, mediated via GABA B synapses.

Neurochemical and neuropharmacological indications for the involvement of GABA and glycine receptors in neuropsychiatric disorders.

From binding studies using 3H-GABA and 3H-strychnine in dissected human brain material, inhibitory amino acid neurotransmitter receptors have a widespread distribution in the human CNS. Generally GABA receptors are predominant in the forebrain and upper brainstem whereas glycine receptors are more localized in the lower brainstem and spinal cord. Some areas (eg. the substantia nigra) have appreciable quantities of both receptors. Although glycine receptors are altered in some pathological conditions (eg. in Parkinson's disease, in the substantia nigra) the neuropharmacology of the glycine system is still poorly understood. On the other hand the GABA system has been intensively studied. Dysfunction of GABA receptors occurs in various neurological states, as epilepsy, Parkinson's disease and Huntington's chorea. Furthermore GABA agonists are active in animal models for dyskinesia, epilepsy and depression, amongst others. Clinical studies with progabide confirm these findings in animal models, and suggest that low-medium affinity GABA agonists are more appropriate clinical agents than are high or very high affinity GABA agonists. From these and many other findings there appears to be a very large potential for creating new pharmacological agents for different neuropsychiatric disorders based on agonist activity at inhibitory amino-acid receptors. From the example of progabide these compounds can be made not only specific for the receptor involved, but also to have a lower incidence of neurotoxic effects than presently available drugs.

The action of arachidonic acid on the locomotive activity of mice.

The intraperitoneal administration of methyl or sodium arachidonate (100 and 200 mg-kg causes, in mice, a significant decline in locomotive activity 30 min later, and is able to oppose completely the antagonistic action of D-amphetamine (2.5 and 5 mg-kg). This effect seems to be related to increased synthesis of prostaglandins, for it disappears partially after pretreatment with acetylsalicylic acid, which alone has no effect on the spontaneous activity of mice. Oleic acid, an unsaturated fatty acid not involved in prostaglandin synthesis does not give significant results in the same conditions.